Advertisement


Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

2024 ASCO Annual Meeting

Advertisement

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Today we're going to present data about the arm six and seven from the NHL-2 trial. And these are exciting because they are combinations of epcoritamab, a bispecific antibody, with different standards of care for different subsets of lymphoma. So the arm six and arm seven are treating patients in primarily frontline follicular lymphoma, and the arm six trial is combining epcoritamab with a standard of care, rituximab plus Revlimid, lenalidomide. We sometimes call it R-squared. And the arm six is 41 patients with epcoritamab plus R-squared. Primary endpoints here are efficacy. And this was very exciting because R-squared, a standard of care, are very good therapy, but a very imperfect therapy. We have probably less than half of patients, about 48%, in the big RELEVANCE trial from a few years ago with R-squared getting complete remissions. So good, but a lot of room for improvement. And the big punchline of the epcoritamab plus R-squared arm six is that 85% of patients were having complete remissions, quite awesome, and the vast majority of those remissions were ongoing for at least more than 18 months. Median follow up here was about 22 months. So most of these remissions appear to be durable. And again, most patients on the study had complete remissions. And this is despite the fact that these were a standard cohort of patients, about average age for most follicular lymphoma trials, and the majority with advanced stage, the majority with FLIPI scores of two to five. So in this now medium-sized trial, 40 patients, great results and pretty good durability of those remissions. And the safety here looked to be very good. Most of the side effects that we saw were similar to those to R-squared alone. And the epcoritamab-specific side effects that we saw were a couple, primarily cytokine release syndrome. CRS in this trial was completely low-grade, grade one, grade two. About half of patients had CRS, but, again, low-grade and most of those grade one. So other than that, the safety seemed to be similar to R-squared in most ways. There was neutropenia in about 44% of patients, but no febrile neutropenia, the thing we worry most about. And so this is such positive data that we're excited to see further development of this regimen. There are ongoing trials now for epcor plus R-squared in the frontline, a randomized trial, and also for second-line follicular lymphoma patients. And I'll just say a little bit about arm seven of the trial. This is studying maintenance epcoritamab therapy after any standard of care induction, mostly for patients in the first-line. There was a small number of patients in the second-line or beyond, but primarily frontline patients who were in partial or complete remission from whatever their standard of care, R-chemo or otherwise, was. And the exciting result here was that, out of 20 patients, all of the patients who were in a partial remission going to the trial then transferred into complete remission. And these complete remissions, again, for almost all of the patients, appear to be quite durable. Again, median follow up here, just beyond 22 months. So we can use epcoritamab as part of a frontline combination regimen, and we can use it as a maintenance afterwards. And the safety signals, again, low-grade CRS, no patients having grade three or above CRS, and overall grade one CRS in about a third of patients. So, pretty well tolerated, pretty durable remission so far. Another way we can incorporate these novel immunotherapies into or just after frontline therapies.

Related Videos

Prostate Cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

Leukemia

Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Lung Cancer

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).

Lung Cancer

Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study

Narjust Florez, MD, of Dana-Farber Cancer Institute, and David R. Spigel, MD, of Sarah Cannon Research Institute, discuss phase III findings showing that durvalumab as consolidation treatment after concurrent platinum-based chemoradiotherapy improved survival outcomes compared with placebo in patients with limited-stage small cell lung cancer. According to Dr. Spigel, these data support durvalumab as a new standard of care in this population (Abstract LBA5).

Advertisement

Advertisement




Advertisement